Swiss National Bank
ALNY icon

Swiss National Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

Swiss National Bank’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113M Sell
374,080
-13,640
-4% -$4.11M 0.06% 264
2026
Q1 		$128M Buy
387,720
+28,520
+8% +$9.71M 0.07% 228
2025
Q4 		$143M Sell
359,200
-16,600
-4% -$7.35M 0.09% 190
2025
Q3 		$171M Sell
375,800
-18,000
-5% -$7.33M 0.1% 168
2025
Q2 		$128M Buy
393,800
+29,600
+8% +$8.19M 0.08% 227
2025
Q1 		$98.3M Buy
364,200
+1,600
+0.4% +$411K 0.07% 248
2024
Q4 		$85.3M Sell
362,600
-12,800
-3% -$3.37M 0.06% 292
2024
Q3 		$103M Buy
375,400
+1,000
+0.3% +$260K 0.07% 264
2024
Q2 		$91M Sell
374,400
-1,500
-0.4% -$237K 0.06% 270
2024
Q1 		$56.2M Sell
375,900
-14,900
-4% -$2.49M 0.04% 390
2023
Q4 		$74.8M Sell
390,800
-9,800
-2% -$1.67M 0.05% 315
2023
Q3 		$70.9M Sell
400,600
-47,000
-11% -$8.97M 0.06% 313
2023
Q2 		$85M Sell
447,600
-40,700
-8% -$8.07M 0.06% 319
2023
Q1 		$97.8M Buy
488,300
+200
+0% +$42K 0.07% 292
2022
Q4 		$116M Sell
488,100
-35,510
-7% -$7.57M 0.08% 245
2022
Q3 		$105M Buy
523,610
+2,200
+0.4% +$420K 0.08% 257
2022
Q2 		$76M Buy
521,410
+3,400
+0.7% +$482K 0.05% 344
2022
Q1 		$84.6M Buy
518,010
+66,300
+15% +$10.1M 0.05% 361
2021
Q4 		$76.6M Sell
451,710
-12,900
-3% -$2.4M 0.05% 376
2021
Q3 		$87.7M Sell
464,610
-12,300
-3% -$2.31M 0.06% 329
2021
Q2 		$80.8M Buy
476,910
+30,086
+7% +$4.41M 0.05% 368
2021
Q1 		$63.1M Buy
446,824
+8,800
+2% +$1.32M 0.04% 431
2020
Q4 		$56.9M Sell
438,024
-8,900
-2% -$1.19M 0.04% 431
2020
Q3 		$65.1M Buy
446,924
+1,500
+0.3% +$213K 0.05% 346
2020
Q2 		$66M Buy
445,424
+12,800
+3% +$1.73M 0.06% 332
2020
Q1 		$47.1M Buy
432,624
+82,000
+23% +$9.47M 0.05% 358
2019
Q4 		$40.4M Sell
350,624
-14,800
-4% -$1.48M 0.04% 431
2019
Q3 		$29.4M Buy
365,424
+53,524
+17% +$4.23M 0.03% 500
2019
Q2 		$22.6M Buy
311,900
+9,100
+3% +$698K 0.02% 562
2019
Q1 		$28.3M Buy
302,800
+8,500
+3% +$711K 0.03% 508
2018
Q4 		$21.5M Buy
294,300
+5,400
+2% +$415K 0.03% 527
2018
Q3 		$25.3M Sell
288,900
-7,700
-3% -$775K 0.03% 534
2018
Q2 		$29.2M Buy
296,600
+13,700
+5% +$1.36M 0.03% 509
2018
Q1 		$33.7M Sell
282,900
-43,600
-13% -$5.62M 0.04% 447
2017
Q4 		$41.5M Buy
326,500
+188,600
+137% +$23.7M 0.04% 424
2017
Q3 		$16.2M Hold
137,900
– – 0.02% 604
2017
Q2 		$11M Buy
137,900
+10,200
+8% +$652K 0.01% 658
2017
Q1 		$6.54M Buy
127,700
+800
+0.6% +$37K 0.01% 833
2016
Q4 		$4.75M Sell
126,900
-85,900
-40% -$3.6M 0.01% 981
2016
Q3 		$14.4M Sell
212,800
-2,100
-1% -$148K 0.02% 577
2016
Q2 		$11.9M Buy
214,900
+16,700
+8% +$1.05M 0.02% 608
2016
Q1 		$11.9M Buy
198,200
+59,900
+43% +$3.98M 0.02% 594
2015
Q4 		$13M Buy
138,300
+3,400
+3% +$315K 0.03% 512
2015
Q3 		$10.8M Buy
134,900
+13,000
+11% +$1.44M 0.03% 544
2015
Q2 		$14.6M Buy
121,900
+39,100
+47% +$4.67M 0.04% 470
2015
Q1 		$8.65M Buy
82,800
+11,200
+16% +$1.13M 0.02% 590
2014
Q4 		$6.95M Buy
71,600
+3,700
+5% +$343K 0.03% 568
2014
Q3 		$5.3M Buy
67,900
+7,100
+12% +$458K 0.02% 667
2014
Q2 		$3.84M Sell
60,800
-2,700
-4% -$160K 0.01% 867
2014
Q1 		$4.26M Buy
63,500
+14,400
+29% +$1.11M 0.02% 791
2013
Q4 		$3.16M Buy
49,100
+500
+1% +$29.8K 0.01% 816
2013
Q3 		$3.11M Sell
48,600
-2,200
-4% -$110K 0.01% 774
2013
Q2 		$1.57M Buy
+50,800
New +$1.35M 0.01% 1131

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Swiss National Bank's ALNY Position: Q2 2026 in Review

Swiss National Bank reduced its Alnylam Pharmaceuticals (ALNY) stake by 3.5% in Q2 2026, selling an estimated $4.11M and leaving 374,080 shares worth $113M. The position accounts for 0.06% of the portfolio, ranked #264.

Swiss National Bank first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $171M in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Swiss National Bank held 374,080 shares of Alnylam Pharmaceuticals worth $113M as of Q2 2026.
  • Swiss National Bank sold 13,640 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $4.11M.
  • Alnylam Pharmaceuticals made up 0.06% of Swiss National Bank's portfolio in Q2 2026, its #264 holding.
  • Swiss National Bank first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Swiss National Bank's Alnylam Pharmaceuticals position peaked at $171M in Q3 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.